Other studies have shown that there is a positive relationship between the expression of ALK and integrin β3 in NSCLC patients with ALK rearrangements, and patients with NSCLC with ALK rearrangements can be treated with ALK inhibitors [53]. Here, ALK is linked to non-small cell lung carcinoma.